BACKGROUND: Coronavirus disease 2019 (COVID-19) may leave behind an altered health status early after recovery. We evaluated the clinical status of COVID-19 survivors at three months after hospital discharge. METHODS: In this prospective observational cohort study, hospitalized patients aged ≥18 years, evaluated at one (M1) and three (M3) months post-discharge were enrolled. 251 patients (71.3% males, median [IQR] age 61.8 [53.5-70.7] years) were included. Median (IQR) time from discharge to M3 was 89 (79.5-101) days. Primary outcome was residual respiratory dysfunction (RRD), defined by tachypnea, moderate to very severe dyspnea, or peripheral oxygen saturation ≤95% on room air at M3. RESULTS: RRD was found in 30.4% of patients, with no significant difference compared with M1. Chronic obstructive pulmonary disease and length of stay were independent predictors of RRD at multivariable logistic regression (odds ratio, OR, [95% confidence interval, CI] 4.13 [1.17-16.88], p 0.033; OR [95% CI] 1.02 [1.00-1.04], p 0.047, respectively). Obesity and C-reactive protein levels upon admission were additional predictors at regression tree analysis. Impaired quality of life (QoL) was reported by 53.2% of patients. Anxiety and insomnia were each present in 25.5% of patients, and PTSD in 22.4%. No difference was found between M1 and M3 in QoL, anxiety or PTSD. Insomnia decreased at M3. Current major psychiatric disorder as well as anxiety, insomnia and PSTD at M1 independently predicted PTSD at M3. CONCLUSIONS: Clinical damage may persist at three months after discharge in COVID-19 survivors. Post-recovery follow-up is an essential component of patient management.
BACKGROUND:Coronavirus disease 2019 (COVID-19) may leave behind an altered health status early after recovery. We evaluated the clinical status of COVID-19 survivors at three months after hospital discharge. METHODS: In this prospective observational cohort study, hospitalized patients aged ≥18 years, evaluated at one (M1) and three (M3) months post-discharge were enrolled. 251 patients (71.3% males, median [IQR] age 61.8 [53.5-70.7] years) were included. Median (IQR) time from discharge to M3 was 89 (79.5-101) days. Primary outcome was residual respiratory dysfunction (RRD), defined by tachypnea, moderate to very severe dyspnea, or peripheral oxygen saturation ≤95% on room air at M3. RESULTS: RRD was found in 30.4% of patients, with no significant difference compared with M1. Chronic obstructive pulmonary disease and length of stay were independent predictors of RRD at multivariable logistic regression (odds ratio, OR, [95% confidence interval, CI] 4.13 [1.17-16.88], p 0.033; OR [95% CI] 1.02 [1.00-1.04], p 0.047, respectively). Obesity and C-reactive protein levels upon admission were additional predictors at regression tree analysis. Impaired quality of life (QoL) was reported by 53.2% of patients. Anxiety and insomnia were each present in 25.5% of patients, and PTSD in 22.4%. No difference was found between M1 and M3 in QoL, anxiety or PTSD. Insomnia decreased at M3. Current major psychiatric disorder as well as anxiety, insomnia and PSTD at M1 independently predicted PTSD at M3. CONCLUSIONS: Clinical damage may persist at three months after discharge in COVID-19 survivors. Post-recovery follow-up is an essential component of patient management.
Authors: Susanne Rabady; Johann Altenberger; Markus Brose; Doris-Maria Denk-Linnert; Elisabeth Fertl; Florian Götzinger; Maria de la Cruz Gomez Pellin; Benedikt Hofbaur; Kathryn Hoffmann; Renate Hoffmann-Dorninger; Rembert Koczulla; Oliver Lammel; Bernd Lamprecht; Judith Löffler-Ragg; Christian A Müller; Stefanie Poggenburg; Hans Rittmannsberger; Paul Sator; Volker Strenger; Karin Vonbank; Johannes Wancata; Thomas Weber; Jörg Weber; Günter Weiss; Maria Wendler; Ralf-Harun Zwick Journal: Wien Klin Wochenschr Date: 2021-12-01 Impact factor: 1.704
Authors: Sara Nowakowski; Manasa Kokonda; Rizwana Sultana; Brittany B Duong; Sarah E Nagy; Mohammed F Zaidan; Mirza M Baig; Bryan V Grigg; Justin Seashore; Rachel R Deer Journal: Brain Sci Date: 2022-04-30
Authors: Alberto Zangrillo; Alessandro Belletti; Diego Palumbo; Maria Rosa Calvi; Francesca Guzzo; Evgeny V Fominskiy; Alessandro Ortalda; Pasquale Nardelli; Marco Ripa; Martina Baiardo Redaelli; Giovanni Borghi; Giovanni Landoni; Filippo D'Amico; Marilena Marmiere; Beatrice Righetti; Margherita Rocchi; Marco Saracino; Moreno Tresoldi; Lorenzo Dagna; Francesco De Cobelli Journal: J Cardiothorac Vasc Anesth Date: 2021-11-27 Impact factor: 2.628
Authors: Sarah Houben-Wilke; Yvonne Mj Goërtz; Jeannet M Delbressine; Anouk W Vaes; Roy Meys; Felipe Vc Machado; Maarten van Herck; Chris Burtin; Rein Posthuma; Frits Me Franssen; Herman Vijlbrief; Yvonne Spies; Alex J van 't Hul; Martijn A Spruit; Daisy Ja Janssen Journal: JMIR Ment Health Date: 2022-02-24